Shares of Unilife Corporation (ASX: UNS) have more than doubled in price today, rising as much as 150% at one point to a high of 30 cents. They’ve since retreated to 29 cents, up 142% for the day.
So What: Based in the United States, Unilife is a small healthcare business that designs, develops, manufactures and supplies injectable drug delivery systems that can both enhance and differentiate the drugs or vaccines being delivered.
Today’s strong gains came after the group announced it had entered into a Material Definitive Agreement with Amgen Inc., which also paid Unilife a $15 million non-refundable deposit. The agreement follows Unilife’s previous announcement stating it was reviewing strategic alternatives and partnerships, together with the licensing of some of its proprietary products.
Unilife will develop, manufacture and supply wearable injector devices for use in certain large volume drug products of Amgen, as well as some small-volume drug products, with Amgen to pay Unilife an amount for each device it manufactures.
Now What: Although shareholders will no doubt be pleased to see their shares more than double in price today, many are still sitting on a painful loss over the last 12 months. Indeed, the shares recently hit a low of just 10 cents, down from $1 in February.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can follow Ryan on Twitter @ASXvalueinvest.
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.